Prognostic value of partial genetic instability in neuroblastoma with ≤50% neuroblastic cell content

Histopathology

Volumn 59, Issue 1, 2011, Pages 22-30

  Piqueras, Marta ^a   Navarro, Samuel ^a   Cañete, Adela ^a   Castel, Victoria ^a   Noguera, Rosa ^a,b  

^a UNIVERSITY OF VALENCIA   (Spain)

^b HOSPITAL INFANTIL LA FE   (Spain)

Author keywords

Fluorescence in situ hybridization; Genome instability; Neuroblastoma; Prognostic factors; Tissue microarray

Indexed keywords

ARTICLE; CANCER GENETICS; CANCER SURVIVAL; CHROMOSOME 11Q; CHROMOSOME 17Q; CHROMOSOME 1P; FLUORESCENCE IN SITU HYBRIDIZATION; GENE; GENE DELETION; GENETIC MARKER; GENOMIC INSTABILITY; HIGH RISK PATIENT; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; MYCN GENE; NEUROBLASTOMA; NEUROBLASTOMA CELL; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PRIMARY TUMOR; PRIORITY JOURNAL; PROGNOSIS; TISSUE MICROARRAY;

ADOLESCENT; CELL COUNT; CHILD; CHILD, PRESCHOOL; CHROMOSOMES, HUMAN, PAIR 1; CHROMOSOMES, HUMAN, PAIR 11; CHROMOSOMES, HUMAN, PAIR 17; GENETIC MARKERS; GENOMIC INSTABILITY; HUMANS; IN SITU HYBRIDIZATION, FLUORESCENCE; INFANT; INFANT, NEWBORN; KAPLAN-MEIER ESTIMATE; MULTIVARIATE ANALYSIS; NEUROBLASTOMA; NUCLEAR PROTEINS; ONCOGENE PROTEINS; PROGNOSIS; TISSUE ARRAY ANALYSIS; YOUNG ADULT;

EID: 79960444332     PISSN: 03090167     EISSN: 13652559     Source Type: Journal    
DOI: 10.1111/j.1365-2559.2011.03899.x     Document Type: Article

References (19)

1. Heck JE, Ritz B, Hung RJ, Hashibe M, Boffetta P. The epidemiology of neuroblastoma: a review. Paediatr. Perinat. Epidemiol. 2009; 23; 125-143.
2. Bowen KA, Chung DH. Recent advances in neuroblastoma. Curr. Opin. Pediatr. 2009; 21; 350-356.
3. Van Roy N, De Preter K, Hoebeeck J et al. The emerging molecular pathogenesis of neuroblastoma: implications for improved risk assessment and targeted therapy. Genome Med. 2009; 1; 74.
4. Cohn SL, Pearson AD, London WB et al. The International Neuroblastoma Risk Group (INRG) classification system: an INRG Task Force report. J. Clin. Oncol. 2009; 27; 289-297.
5. Attiyeh EF, London WB, Mosse YP et al. Chromosome 1p and 11q deletions and outcome in neuroblastoma. N. Engl. J. Med. 2005; 353; 2243-2253.
6. Maris JM, Hogarty MD, Bagatell R, Cohn SL. Neuroblastoma. Lancet 2007; 369; 2106-2120.
7. Janoueix-Lerosey I, Schleiermacher G, Michels E et al. Overall genomic pattern is a predictor of outcome in neuroblastoma. J. Clin. Oncol. 2009; 27; 1026-1033.
8. Ambros PF, Ambros IM, Brodeur GM et al. International consensus for neuroblastoma molecular diagnostics: report from the International Neuroblastoma Risk Group (INRG) Biology Committee. Br. J. Cancer 2009; 100; 1471-1482.
9. Schleiermacher G, Michon J, Huon I et al. Chromosomal CGH identifies patients with a higher risk of relapse in neuroblastoma without MYCN amplification. Br. J. Cancer 2007; 97; 238-246.
10. Villamon E, Piqueras M, Mackintosh C et al. Comparison of different techniques for the detection of genetic risk-identifying chromosomal gains and losses in neuroblastoma. Virchows Arch. 2008; 453; 47-55.
11. Villamon E, Piqueras M, Berbegall AP et al. Comparative study of MLPA-FISH to determine DNA copy number alterations in neuroblastic tumours. Histol. Histopathol. 2011 Mar;26(3):343-350.
12. Piqueras M, Navarro S, Castel V, Canete A, Llombart-Bosch A, Noguera R. Analysis of biological prognostic factors using tissue microarrays in neuroblastic tumours. Pediatr. Blood Cancer 2009; 52; 209-214.
13. Ambros IM, Benard J, Boavida M et al. Quality assessment of genetic markers used for therapy stratification. J. Clin. Oncol. 2003; 21; 2077-2084.
14. Mathew P, Valentine MB, Bowman LC et al. Detection of MYCN gene amplification in neuroblastoma by fluorescence in situ hybridization: a pediatric oncology group study. Neoplasia 2001; 3; 105-109.
15. Spitz R, Hero B, Ernestus K, Berthold F. FISH analyses for alterations in chromosomes 1, 2, 3, and 11 define high-risk groups in neuroblastoma. Med. Pediatr. Oncol. 2003; 41; 30-35.
16. Stallings RL, Yoon K, Kwek S, Ko D. The origin of chromosome imbalances in neuroblastoma. Cancer Genet. Cytogenet. 2007; 176; 28-34.
17. Canete A, Gerrard M, Rubie H et al. Poor survival for infants with MYCN-amplified metastatic neuroblastoma despite intensified treatment: the International Society of Paediatric Oncology European Neuroblastoma Experience. J. Clin. Oncol. 2009; 27; 1014-1019.
18. De Bernardi B, Gerrard M, Boni L et al. Excellent outcome with reduced treatment for infants with disseminated neuroblastoma without MYCN gene amplification. J. Clin. Oncol. 2009; 27; 1034-1040.
19. Vermeulen J, De Preter K, Naranjo A et al. Predicting outcomes for children with neuroblastoma using a multigene-expression signature: a retrospective SIOPEN/COG/GPOH study. Lancet Oncol. 2009; 10; 663-671.